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Background and Purpose Micro ribonucleic acid-150-5p (miR-150-5p) regulates proinflammatory 
cytokines as well as vessel integrity. We evaluated the incremental prognostic value of logarithm 
(log) of miR-150-5p plasma levels after ischemic stroke.
Methods In a prospective cohort study, levels of miR-150-5p were measured within 72 hours of 
symptom onset in 329 ischemic stroke patients. The outcome measures were unfavorable 
functional outcome (assessed by the modified Rankin Scale score >2) and mortality within 90 
days. Logistic regression and Cox proportional hazards models were fitted to estimate odds ratio 
(OR), respectively hazard ratio (HR) and 95% confidence interval (CI) for the association between 
log-miR-150-5p and the outcome measures. The discriminatory accuracy was assessed with the 
area under the receiver-operating-characteristic curve (AUC) and the incremental prognostic 
value was estimated with the net reclassification index.
Results After adjusting for demographic and vascular risk factors, lower log-miR-150-5p levels 
were independently associated with mortality (HR 0.21 [95% CI, 0.08–0.51], P=0.001) but not 
functional outcome (OR 1.10 [95% CI, 0.54–2.25], P=0.79). Adding log-miR-150-5p improved the 
discriminatory accuracy of the best multivariate model to predict mortality from an AUC of 0.91 
(95% CI, 0.88–0.95) to 0.92 (95% CI, 0.88–0.96 Likelihood-ratio test-P<0.001), and resulted in a 
net reclassification index of 37.3% (95% CI, 0.28–0.52).
Conclusions In patients with ischemic stroke, log-miR-150-5p is a novel prognostic biomarker, 
highly associated with mortality within 90 days, improving risk classification beyond traditional 
risk factors. 
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Introduction
Knowledge of the important factors that affect prognosis of 
stroke is necessary to accurately predict outcome of patients, to 
provide a rational approach to patient management, and to un-
derstand the disease development. 
Some clinical scores have been proposed to predict func-
tional outcome1 and mortality,2 however there is room for 
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improvement. Rapidly measurable biomarkers, which are as-
sociated with disease development, functional outcome and 
mortality, may improve the prognostic accuracy of tradi-
tional risk factors. However, to be clinically useful in the 
setting of acute stroke, blood biomarkers have to add prog-
nostic information to already established risk factors such 
as stroke severity and age.3 The search for such biomarkers 
has become increasingly popular4 however only in very few 
cases,5 they showed incremental predictive value. 
MiRNAs are short (approximately 22 nucleotides) noncod-
ing RNA molecules involved in post-transcriptional gene 
regulation.6 Their presence and stability in the bloodstream 
led to the hypothesis that they might serve as biomarkers.7 
In cardiovascular diseases, circulating levels of micro ribo-
nucleic acid-150-5p (miR-150-5p) were found to be associ-
ated with outcome after acute myocardial infarction.8 Ex-
pressed mainly by monocytes, miR-150-5p acts as both an 
endocrine factor leading to anti-inflammatory effects9 and 
a paracrine factor leading to vascular endothelial cell mi-
gration.10 In view to our study, other authors described that 
the expression of miR-150 was decreased in brain and se-
rum of rats subjected to cerebral ischemia.11 Due to its abil-
ity to regulate vessel integrity and pro-inflammatory cyto-
kines secretion, mediators of cellular communication in the 
ischemic brain, we hypothesized that miR-150-5p may in-
form about the prognosis of patients with acute ischemic 
stroke. In this study, we measured the plasma levels of miR-
150-5p in a cohort of 329 patients with acute ischemic stroke 
and we determined their incremental predictive value over tra-
ditional demographic and vascular risk factors.
Methods
Study design and setting
The design of the prospective cohort used in the present study 
(https://www.clinicaltrials.gov/; NCT00390962) has been de-
scribed in detail elsewhere.12 A flow-chart of the present study 
is provided in Figure 1. Briefly, 605 patients with suspected 
ischemic cerebrovascular events presenting at the emergency 
department between October 2006 and October 2007 were 
screened. Of these, 362 patients had an ischemic stroke accor-
ding to the World Health Organization (WHO) criteria, 359 
completed follow up (99.2%), and 329 had plasma samples 
available for the analysis of logarithm (log)-miR-150-5p. Initial 
ischemic stroke was defined upon to the WHO criteria as an 
acute focal neurological deficit lasting longer than 24 hours13 
with no sign of acute intracranial bleeding on cerebral ima-
ging. Missing informed consent or any diagnosis different from 
ischemic stroke (i.e., stroke mimics) were exclusion criteria. The 
study was approved by the Ethics Committee of Basel, Switzer-
land and was conducted according to the principles expressed 
in the Declaration of Helsinki. All patients or the patients’ next 
of kin provided written informed consent for the collection of 
data, blood samples, and subsequent analyses. 
Clinical baseline variables
The following data were collected with a standardized bed-side 
interview and complete chart review on admission: vital signs, 
co-morbidities as assessed by the Charlson Comorbidity Index 
adjusted for stroke (such as age, gender, smoking habits, histo-
ry of hypercholesterolemia, hypertension, diabetes mellitus, 
previous stroke, positive family history for stroke and history of 
coronary heart disease), medication at the time of index ische-
mic stroke and cardiovascular risk factors (i.e., age, sex, smo-
king habits, history of hypercholesterolemia, hypertension, dia-
betes mellitus, previous stroke, positive family history for myo-
cardial infarction, stroke and history of coronary heart disease). 
Stroke physicians prospectively recorded the National Institute 
of Health Stroke Scale (NIHSS) score14 upon admission. Stroke 
etiology was determined according to the criteria of the Trial 
of ORG 10172 in Acute Stroke Treatment (TOAST) criteria,15 
which distinguishes large-artery atherosclerosis, cardioembo-
lism, small-artery occlusion, other etiology and undetermined 
etiology. 
Blood sampling
In all patients the routine admission laboratory tests consisted 
Figure 1. Flowchart of patient’s enrollment and follow up. From 605 
screened patients, ischemic stroke was diagnosed in 362 patients. 359 pa-
tients completed follow-up and were finally included in the analysis. Of 
these, 30 patients were excluded from the analysis because of missing 
plasma samples for miR-150-5p determination.
243 not analysed
 107  transient ischemic attack
  66  onset of symptoms >72 hours
  42  haemorrhagic stroke
  10  epileptic seizures
  9  migraine
  6  no informed consent
  2  cerebral tumor
  1  spinal ischemial
2 lost to follow-up
1 withdrawal of informed consent 
no miR-150-5p measurements (n=30) 
605 patients with suspected 
ischemic cerebrovascular event 
evaluated for study inclusion
329 patients included in
final analysis
362 ischemic stroke
Vol. 19 / No. 3 / September 2017
https://doi.org/10.5853/jos.2017.00423 http://j-stroke.org 325
of at least the following parameters, C- reactive protein (CRP), 
creatinine, glucose, cholesterol, triglycerides and white blood 
cells. In addition, for miR-150-5p assessment, plasma samples 
were collected in EDTA tubes on admission within 72 hours 
from symptom onset. These tubes were all centrifuged within 5 
minutes, aliquoted and frozen at -70°C within 20 minutes from 
blood draw, for future analyses.
MiR-150-5p assessment
Circulating levels of miR-150-5p were measured blinded to 
clinical outcomes, as described in details elsewhere.16 Briefly, 
total RNA was extracted from plasma samples with the mirVa-
na PARIS kit (Ambion, Applied Biosystem, Lennik, Belgium). The 
elution volume was 50 µL, of which 12 µL were used as input 
for Reverse-transcription. No enrichment for small RNAs was 
performed. The synthetic C. elegans miR-39 (Qiagen, Venlo, the 
Netherlands), which is devoid of sequence homology to human 
miRNAs, was added to plasma samples after lysis to correct for 
extraction efficiency. Potential DNA contamination was elimi-
nated using DNase (Qiagen). RNA was reverse transcribed with 
the miScript reverse transcription kit (Qiagen) and the resulting 
cDNA was diluted 10-fold before quantitative polymerase 
chain reaction (PCR) with the miScript SYBRgreen PCR kit 
(Qiagen). MiR-150-5p-specific miScript primers were obtained 
from Qiagen. An inter-run calibrator was included in each PCR 
plate to correct for inter-run technical variations.
Expression levels were normalized with cel-miR-39 accor-
ding to the formula (2exp[Ct cel-miR-39/Ct miR-150-5p]), and 
are expressed as number of copies of miR-150-5p per µL of 
plasma, as previously described for other miRNAs.17
Outcome measures
Trained stroke physicians and study nurses assessed outcome 
three months after the acute stroke with a structured follow-
up telephone interview. They were blinded to log-miR-150-5p 
levels and baseline clinical variables.  
 The outcome measures were unfavorable functional outcome 
defined as a modified Rankin Scale (mRS) score of >2 points and 
mortality. As secondary outcome measure we used the mRS as 
ordinal variable (ordinal scale from 0 to 6 points). All outcome 
measures were assessed at 90 days after the index stroke.
Neuroimaging
Ischemic stroke was a clinical diagnosis according to the WHO 
criteria, but computed tomography was performed in all pati-
ents on admission mainly to exclude intracranial hemorrhage. 
Additionally, magnetic resonance imaging with diffusion-
weighted imaging was performed in 188 patients (57.1%). Dif-
fusion-weighted imaging lesion volumes were measured by the 
consensus of two experienced raters unaware of the clinical 
and laboratory findings. A semi-quantitative method validated 
for ischemic stroke lesions was used to calculate the lesion 
size.18 Lesions were ranked into three size classes to represent 
typical stroke patterns: (1) small lesion with a volume of <10 
mm3, (2) medium lesion of 10–100 mm3, (3) large lesion with a 
volume of more than 100 mm3.12
Statistical analysis
Statistical analysis was performed for both outcome measures 
separately. Discrete variables are expressed as frequency (per-
centage), continuous variables as medians with interquartile 
ranges (IQR). The distribution of raw biomarker data was 
skewed. After log transformation with a base of 10, the distri-
bution of the biomarker data approximated a normal distribu-
tion. Thus one-unit increase of log-miR-150-5p corresponds to 
a tenfold increase in miR-150-5p levels. 
Two group comparisons for categorical baseline measure-
ments were performed by Fisher’s exact test and for continu-
ous, not normally distributed baseline data, by the Mann-
Whitney U test. For simple survival analysis, we stratified pa-
tients according to log-miR-150-5p quartiles in Kaplan Meier 
curves and compared the groups by mean of the log-rank test. 
To assess the independent association of log-miR-150-5p 
levels with our outcome measures, we computed a multivariate 
binary and ordinal logistic and Cox regression model. The final 
multivariate models included variables significantly associated 
with an unfavorable outcome or mortality in the univariate 
analyses (for functional outcome: log-miR-150-5p, CRP, sex, 
atrial fibrillation, Charlson comorbidity index, age, NIHSS, total 
anterior circulation stroke, posterior circulation stroke; for 
mortality: log-miR-150-5p, CRP, atrial fibrillation, age, NIHSS, 
total anterior circulation stroke). We report odds ratio (OR) and 
hazard ratio (HR) along with 95% confidence interval (CI) as 
measure of association and uncertainty, respectively. 
To account for missing values, we performed multiple impu-
tations, which have been recently proposed to be the best ap-
proach for modeling the effects of missing data.19
The variable with the most missing values (i.e., CRP levels) 
included in the multivariate model was absent in 16.7% of all 
included patients. All variables included in the regression anal-
ysis were used in the imputation process as recommended.20
No relevant differences between the results of the model 
with and without the multiple imputations were observed 
(neither regarding the magnitude nor the significance of asso-
ciations), thus, in order to improve the power of the analysis, 
we calculated all further steps (see next paragraph) based on 
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the multiple imputation models. 
The discriminatory value of log-miR-150-5p was assessed 
with the area under the receiver-operating-characteristic curve 
(AUC). For the risk model of comparison, we employed the 
multivariate models described above. As recommended in the 
current statistical literature,21 we calculated continuous (cate-
gory-free) net reclassification index (NRI) since our multivari-
ate models of comparisons have no validated risk categories. 
Statistics were calculated using Stata Statistical Software 
ver. 13.1 (StataCorp LLC, College Station, TX, USA). Testing was 
two-sided and P values less than 0.05 were considered to indi-
cate statistical significance. 
Results
Study population
From 605 screened patients, ischemic stroke was diagnosed in 
362 patients, and 359 completed follow-up.12 329 patients had 
blood samples available for the measurement of miR-150-5p 
(Figure 1). To evaluate the potential time dependence of the 
time of blood draw within the 72 hours after symptom onset 
and the log-miR-150-5p levels we conducted a Kruskal-wallis 
test which showed no statistically significant correlation 
(P=0.62). To assess the effect of “time to blood draw” on the 
association of miR150-5p with the outcome variable mortality, 
we performed a bivariate cox regression analysis with miR-
150-5p as main predictor adjusting for the variable “time to 
blood draw.” MiR150-5p remained independently associated 
with mortality with a HR of 0.17 (95% CI, 0.08–0.36, P<0.00).
The distribution of demographic and vascular risk factors 
was similar between the original cohort of 359 patients (de-
tails provided in an earlier report5) and the 329 patients with 
available blood samples used in the present study.
As shown in Table 1, the median age of the present cohort of 
329 patients was 75 years (IQR 65–82), identical to the original 
cohort of 359 patients (75 years [IQR 63–83]). 41% of the 329 
patients were women (original cohort 41%). The most common 
cardiovascular risk factor was arterial hypertension, which was 
present in 76% of patients (original cohort 77%). At admission, 
the median NIHSS score was 5 (IQR 2–10) (original cohort 5 
[IQR 2–10]), and the median log-miR-150-5p concentration 
was 1,357.1 copies per µL of plasma (IQR 755.8-2,869.3). 
Log-miR-150-5p and functional outcome at 90 
days
A total of 134 (40.7%) patients had an unfavorable outcome 
after 90 days. Patients with unfavorable outcome were older, 
suffered more often from arterial hypertension and had a 
higher NIHSS score on admission (Table 2). The median log-
miR-150-5p concentration was lower in patients who had an 
unfavorable outcome at 90 days as compared to patients with 
a favorable outcome (Table 2). In the univariate model, lower 
log-miR-150-5p levels were associated with unfavorable func-
tional outcome with an OR of 0.47 (95% CI, 0.28–0.78, 
P<0.01). However, in the multivariate analysis, log-miR-150-5p 
was no longer associated with unfavorable functional outcome 
(OR 1.10 [95% CI, 0.54–2.55], P=0.79) (Table 3). The same was 
observed when using standardized micro RNA levels as odds 
ratio per 1-SD instead of log levels (OR 1.21 [95% CI, 0.87–
1.68], P=0.27). When analyzing functional outcome as ordinal 
scale (mRS 1–6 points) we also did not find an independent 
association of log-miR-150-5p (P=0.19). The multivariate lo-
gistic model was well calibrated as assessed by the Hosmer and 
Lemeshow goodness-of-fit test (P=0.27).
Log-miR-150-5p and mortality within 90 days
A total of 39 (11.9%) patients died within 90 days after stroke. 
The median log-miR-150-5p concentration was lower in pa-
tients who died within 90 days as compared to survivors (Table 
1). Overall, Kaplan-Meier survival curves of patients stratified 
per log-miR-150-5p quartiles differed (P<0.001, log-rank test) 
(Figure 2). In the univariate Cox model, log-miR-150-5p levels 
were associated with mortality with a HR of 0.18 (95% CI, 
0.08–0.39; P<0.001). 
In the multivariate Cox model, lower log-miR-150-5p concen-
trations independently predicted mortality (HR 0.21 [95% CI, 
0.08–0.51], P=0.001). The same association was found after 
standardization of the log-units of miR-150-5p for mortality 
(HR 0.49 [95% CI, 0.33–0.75], P=0.001). The multivariate Cox 
model was well enough calibrated as assessed by the Groennes-
by and Borgan test (P=0.06). Also miR-150-5p remained inde-
pendently associated with mortality after adjusting for copeptin- 
a well validated prognostic stroke biomarker 5 (0.21 [95% CI, 
0.07–0.63], P<0.01). Log-miR150 and the risk factors which were 
statistically significant in the univariate analyses for mortality 
are shown in the scatter and box plots (Supplementary Figure 1).
Adding log-miR-150-5p improved the discriminatory accura-
cy of the NIHSS alone (AUC from 0.84 [95% CI, 0.83–0.86] to 
0.86 [95% CI, 0.84–0.87], Likelihood-ratio test P<0.001) (Table 
4). Moreover log-miR-150-5p improved the discriminatory ac-
curacy of the whole multivariate model (AUC from 0.91 [95% 
CI, 0.88–0.95] to 0.92 [95% CI, 0.88–0.96], Likelihood-ratio test 
P<0.001) (Table 4). These results were further strengthened by a 
NRI of 37.3% (95% CI, 0.28–0.52) and the pseudo R-squared 
test whose difference of 135.416 in Bayesian-Information-Cri-
terion provides very strong support for our current model. 
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Table 1. Baseline characteristics of all patients as well as stratified by mortality
All patients (n=329) No death (n=290) Death (n=39) P
Demographic data
Age (years) 75 (65–82) 74 (62–82) 82 (78–87) <0.001
Women 136 (41) 119 (41) 17 (44) 0.86
Medical history
Hypertension 251 (76) 219 (76) 32 (82) 0.43
Atrial fibrillation 66 (20) 49 (17) 17 (44) <0.001
Current smoking 116 (35) 105 (36) 11 (28) 0.38
Diabetes mellitus 66 (20) 57 (20) 9 (23) 0.67
Coronary heart disease 84 (26) 69 (24) 15 (38) 0.08
Dyslipidemia 90 (27) 79 (27) 11 (28) 0.85
Previous cerebrovascular event 80 (24) 72 (25) 8 (21) 0.69
Charlson comorbidity Index 1 (0–2) 1 (0–2) 1 (0–2) 0.04
Infections at admission* 21 (6.6) 16 (5.7) 5 (13.5) 0.08
Clinical data
NIHSS at admission (points) 5 (2–10) 4 (2–8) 15 (8–25) <0.001
Stroke syndrome and causative factors 
Total anterior circulation stroke 35 (11) 21 (7) 14 (36) <0.001
Partial anterior circulation stroke 150 (46) 131 (45) 19 (49) 0.73
Lacunar anterior circulation stroke 67 (20) 63 (22) 4 (10) 0.14
Posterior circulation stroke 89 (27) 82 (28) 7 (18) 0.25
Laboratory values
Log-miR-150-5p† 1,357.1 (755.8–2,869.3) 1,452.9 (845.3–3,116.4) 777.3 (577.7–1,326.4) <0.001
Glucose (mmol/L) 6.1 (5.5–7.4) 6.0 (5.4–7.4) 6.3 (6.0–7.5) 0.25
CRP (mg/L)‡ 3.5 (3.0–9.8) 3.2 (3.0–8.6) 14.0 (3.9–43.8) <0.001
White blood cells per µL 8.3 (6.6–9.9) 8.2 (6.6–9.7) 9.3 (6.5–12.1) 0.12
Temperature (°C) 37.0 (36.5–37.5) 37.0 (36.5–37.4) 37.2 (36.4–37.6) 0.79
Lesion size on MR, DWI§ 1.7 (0.2-19.4) 1.5 (0.2-16.4) 40.0 (3.4-146.8) 0.001
Thrombolysis 63 (19.8) 54 (19.1) 38 (20.0) 0.26
TOAST15 subtype
Large-vessel disease 61 (19) 56 (19) 5 (13) 0.39
Cardioembolic 121 (37) 103 (36) 18 (46) 0.22
Small-artery disease 50 (15) 49 (17) 1 (3) 0.02
Other known 15 (5) 14 (5) 1 (3) 1.00
Undetermined 82 (25) 68 (24) 14 (36) 0.11
Time from symptom onset till blood draw
0–3 hours 71 (21.9) 59 (20.7) 12 (30.8) 0.15
3–12 hours 169 (52.2) 151 (52.98) 18 (46.2) 0.50
12–24 hours 48 (14.8) 45 (15.8) 3 (7.7) 0.23
24–72 hours 36 (11.11) 30 (10.5) 6 (15.4) 0.41
Values are presented as median (meaning range between the first and third quartile) or number (%).
NIHSS, National Institute of Health Stroke Scale; CRP, C-reactive protein; MR, magnetic resonance; DWI, diffusion weighted imaging; TOAST, Trial of ORG 
10172 in Acute Stroke Treatment.
*All types of infections including pneumonia on admission or history within the last week; †Log10-transformed values were used, thus one-unit increase cor-
responds to a tenfold increase in normalized copy numbers per µL of plasma. See the “Statistical Analysis” section for details; ‡CRP had missing values (missing 
in 16.7% of patients); §Volume in milliliters. Refers to patients where information on diffusion-weighted imaging lesion was present (n=188).
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Table 2. Baseline characteristics of all patients, stratified by functional outcome
All patients (n=329) Favorable outcome (n=195) Unfavorable outcome (n=134) P
Demographic data
Age (years) 75 (65–82) 68.6 (20.4–94.2) 78.0 (44.6–96.6) <0.001
Women 136 (41) 69 (35.4) 67 (50.0) <0.01
Medical history
Hypertension 251 (76) 142 (72.8) 109 (81.3) 0.09
Atrial fibrillation 66 (20) 29 (14.9) 37 (27.6) <0.01
Current smoking 116 (35) 74 (38.0) 42 (31.3) 0.24
Diabetes mellitus 66 (20) 38 (19.5) 28 (20.9) 0.78
Coronary heart disease 84 (26) 46 (23.6) 38 (28.4) 0.37
Dyslipidemia 90 (27) 58 (29.7) 32 (23.9) 0.26
Previous cerebrovascular event 80 (24) 45 (23.1) 35 (26.1) 0.60
Charlson comorbidity Index 1 (0–2) 1 (0–8) 2 (0–6) <0.001
Infections at admission* 21 (6.6) 9 (4.7) 12 (9.5) 0.11
Clinical data
NIHSS at admission (points) 5 (2–10) 5 (0–23) 11 (0–42) <0.001
OCSP
TACS 35 (11) 8 (4.1) 27 (20.2) <0.001
PACS 150 (46) 87 (44.6) 63 (47.0) 0.74
LACS 67 (20) 42 (21.5) 25 (18.7) 0.58
POCS 89 (27) 61 (31.3) 28 (20.9) 0.04
Laboratory values
MiR-150-5p† 1,357.1 (755.8–2,869.3) 4,103.5 (185.4–180,811.3) 1,980.3 (40.6–11,540.5) 0.01
Glucose (mmol/L) 6.1 (5.5–7.4) 6.6 (3.3–17.2) 6.9 (2.2–24.6) 0.10
White blood cell per µL 3.5 (3.0–9.8) 8.2 (6.5-9.6) 8.3 (6.7-10.2) 0.20
CRP (mg/L)‡ 8.3 (6.6-9.9) 9.9 (3.0–130.4) 24.6 (3.0–302.0) <0.001
Temperature (°C) 37.0 (36.5-37.5) 37.0 (35.0-38.3) 37.0 (35.3-39.9) 0.56
Lesion size on MR, DWI§ 1.7 (0.2-19.4) 12.2 (0.1-153.8) 45.6 (0.1-317.5) <0.001
Thrombolyis 63 (19.8) 38 (20.0) 25 (19.4) 0.51
TOAST15 subtype
Large-vessel disease 61 (19) 36 (18.5) 25 (18.7) 1.00
Cardioembolic 121 (37) 70 (35.9) 51 (38.1) 0.73
Small-artery disease 50 (15) 35 (18.0) 15 (11.2) 0.12
Other known 15 (5) 10 (5.1) 5 (3.7) 0.60
Undetermined 82 (25) 44 (22.6) 38 (28.4) 0.25
Time from symptom onset till blood draw
0–3 hours 71 (21.9) 41 (21.5) 30 (22.6) 0.89
3–12 hours 169 (52.2) 97 (50.8) 72 (54.1) 0.57
12–24 hours 48 (14.8) 31 (16.2) 17 (12.8) 0.43
24–72 hours 36 (11.11) 22 (11.5) 14 (10.5) 0.86
Values are presented as median (meaning range between the first and third quartile) or number (%).
NIHSS, National Institute of Health Stroke Scale; OCSP, Oxfordshire Community Stroke Project; TACS, total anterior circulation syndrome; PACS, partial anteri-
or circulation stroke; LACS, lacunar anterior circulation stroke; POCS, posterior circulation stroke; CRP, C-reactive protein; MR, magnetic resonance; DWI, dif-
fusion weighted imaging; TOAST, Trial of ORG 10172 in Acute Stroke Treatment.
*All types of infections including pneumonia on admission or history within the last week; †Normalized copy number per µL of plasma; ‡CRP had missing val-
ues (missing in 16.7% of patients); §Percentages refer to patients where information on DWI lesion was present (n=188).
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Subgroup of patients with available diffusion-
weighted imaging measurements
Admission magnetic resonance imaging with diffusion-weigh-
ted imaging was available in 188 acute stroke patients (57%). 
Of these, 11 patients died (6%) within 90 days after stroke. 
68% of the patients had a small, 26% a medium and 6% a big 
lesion. In this subgroup of patients, log-miR-150-5p was still 
independently associated with mortality, even after adjustment 
for lesion size (HR 0.17 [95% CI, 0.04–0.77], P=0.02).
Discussion
Our main finding is that lower log-miR-150-5p plasma levels 
were independently associated with mortality but not func-
tional outcome three months after ischemic stroke. Log-miR-
150-5p improved the discriminatory ability of the NIHSS and 
multivariate models as shown by an increase in the respective 
AUCs. Despite the rather modest increase of AUC, log-miR-
150-5p improved risk classification by 37.3% for mortality. 
The pathophysiological mechanisms relating miR-150-5p 
with stroke are not fully unraveled. MiR-150-5p is found to be 
expressed in monocytes,9 endothelial progenitor cells,22 plate-
lets,23 and human coronary artery endothelial cells.24 The influ-
ence of miR-150-5p was described in the context of cell pro-
liferation, migration, and cell differentiation.25 Several mRNA 
targets of miR-150 have been identified and validated, includ-
Table 3. Multivariate logistic regression analysis for functional outcome and cox regression model for mortality 
Predictors
Functional outcome Mortality 
OR 95% CI P HR 95% CI P
Log-miR-150-5p* 1.10 0.54–2.25 0.79 0.21 0.08–0.51 0.001
CRP (mg/L) 1.01 1.00–1.02 0.03 1.01 1.00–1.02 0.001
Age (years) 1.09 1.05–1.12 <0.001 1.05 1.01–1.10 0.01
Sex 1.34 0.75–2.39 0.33
NIHSS at admission (point) 1.15 1.09–1.21 <0.001 1.10 1.06–1.14 <0.001
Charlson comorbidity index (point) 1.45 1.19–1.76 <0.001
Total anterior circulation stroke 3.86 1.24–12.06 0.02 2.51 1.09–5.78 0.03
Atrial fibrillation 0.52 0.25–1.10 0.09 0.82 0.39–1.75 0.62
Posterior circulation stroke 0.79 0.41–1.52 0.48
OR, odds ratio; CI, confidence interval; HR, hazard ratio; CRP, C-reactive protein; NIHSS, National Institute of Health Stroke Scale.
*Log10-transformed values of normalized copy numbers per µL of plasma were used. The variables which were statistically significant in the univariate analy-
sis where included as predictors.
Figure 2. Kaplan-Meier survival estimates for patients stratified by log-
miR-150-5p quartiles. The numbers of patients at risk are indicated at 
multiples of 20 days. Overall, Kaplan–Meier survival curves of patients 
stratified per log-miR-150-5p quartiles differed (P<0.001, log-rank test). Q 
means quartiles of log10-transformed values of miR-150-5p were used in 
these analyses. The x-axis is abridged and shows only the results of the 90 
days after event.
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Table 4. AUC for selected predictors for mortality
Predictors
Mortality
AUC 95% CI P *
NIHSS 0.84 0.83–0.86 <0.001
NIHSS+log miR-150-5p† 0.86 0.84–0.87
Model 1‡ 0.91 0.88–0.95
Model 1‡+log miR-150-5p† 0.92 0.88–0.96 <0.001
AUC, area under the receiver-operating-characteristic curve; CI, confidence 
interval; NIHSS, National Institute of Health Stroke Scale.
*To test the statistical significance of the comparisons of nested vs. whole 
models, the likelihood ratio test was used as recommended;31  
†Log10-transformed values of normalized copy numbers per µL of plasma 
were used; ‡Model 1: includes all variables except log miR-150-5p which 
were statistically significant in the univariate analyses for mortality (C-re-
active protein, age, NIHSS at admission, total anterior circulation stroke, 
atrial fibrillation).
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ing CXCR4,9,22 thereby possibly regulating inflammation which 
can affect the prognosis after stroke. Mobilization and migra-
tion of endothelial progenitor cells are mainly controlled by 
stromal cell-derived factor 1α (SDF-1α) and its receptor CXCR4. 
Furthermore, miR-150 has been shown to regulate cerebral 
angiogenesis through down-regulation of VEGF in a rat model 
of middle cerebral artery occlusion.11 However, a functional in-
volvement of miR-150 in the prognosis after stroke in the 
present study remains at a speculative level and deserves fur-
ther investigation.
In humans, the potential protective role of miR-150-5p has 
also been studied in various other diseases where endothelial 
injury plays a key role. Higher levels of miR-150-5p were asso-
ciated with a lower mortality rate in patients with acute sep-
sis,26 critically ill patients,27 pulmonary arterial hypertension28 
as well as in myocardial infarction.8 In a recent study a poly-
morphism in the gene encoding for miR-150 was found to be 
associated with ischemic stroke.29 Additionally, Cox proportion-
al analysis indicated that the miR-150GA genotype was asso-
ciated with survival in patients with ischemic stroke.29
The available basic and clinical data are in line with our ob-
servation that log-miR-150-5p was associated with a reduced 
mortality after ischemic stroke. However, we did not find a sig-
nificant association with functional outcome. A potential ex-
planation for this observation would be that higher log-miR-
150-5p levels reduce risk of systemic secondary complications 
after stroke, such as myocardial infarction or pneumonia, 
which are associated with higher mortality in this population. 
However, log-miR-150-5p levels may not directly improve for 
example brain plasticity thus explaining the lack of a direct as-
sociation with functional outcome. Alternatively, the protective 
role underlies a threshold effect and miRNA levels below a cer-
tain value reflect a point of no return rather than a gradual as-
sociation with improved functional outcome. The exact mecha-
nisms of the factors that regulate the change of log-miR-150-
5p expression after stroke remain to be fully elucidated. 
Some limitations of our study merit attention. First, plasma 
samples were stored at -70°C for several years before measure-
ment of miR-150-5p, which could potentially lead to some 
degradation. However, degradation would similarly have af-
fected survivors and non-survivors, and it is commonly accept-
ed that miRNAs are stable for several years during -70°C stor-
age. Pre-analytic problems can always affect measurements 
but we only found signs (i.e., change of colour) of potential he-
molysis in 8% of all miR-150-5p measurements in our cohort. 
To assess a potential effect modification, we conducted multi-
variate analysis (Table 3) without and with these samples re-
spectively and didn’t detected any significant changes with 
(HR 0.21 [95% CI, 0.08–0.51], P=0.001) and without hemolysis 
(HR 0.22 [95% CI, 0.08–0.61], P=0.004). Moreover, also hemo-
lysis would similarly have affected survivors and non-survivors.
Second, due to some missing baseline values, we used impu-
tation methods in order to reduce potential bias and retain a 
sufficient level of statistical power. Noteworthy, the direction, 
magnitude as well as significance level of the association of 
log-miR-150-5p with mortality were very similar with and 
without imputation (HR 0.21 [95% CI, 0.08–0.51] and HR 0.17 
[95% CI, 0.06–0.48], respectively). Furthermore, imputation did 
not affect the value of log-miR-150-5p to discriminate those 
who died compared to those who survived (AUC 0.92 [95% CI, 
0.88–0.96] with and 0.91 [95% CI, 0.86–0.96] without imputa-
tion, respectively), this suggests that the results are reliable. 
Third, repeated measurements of log-miR-150-5p or their 
changes over time may be a better indicator of mortality than 
levels measured at a single baseline point. However, such ki-
netic data are currently unavailable. A last limitation is the se-
lection of one candidate miRNA to be included in these analy-
ses, which does not preclude that other miRNAs may have a 
prognostic value after ischemic stroke as well.
Third, developments of new therapeutic approaches in stroke 
could affect the results of this study too. 
Fourth, our NRI could be false positive. For this reason we 
conducted additionally a pseudo R-squared test which 
strengthen our results. Further independent validation cohort 
studies are necessary. 
The strengths of this study include the systematic and pre-
planned collection of clinical data, the highly standardized ac-
quisition and processing of blood within a clear time window 
and the ability to adjust for numerous covariates. Moreover, we 
could assess the prognostic value also in a subgroup of patients 
with measured diffusion-weighted imaging lesions and found 
that log-miR-150-5p was still associated with mortality inde-
pendently of lesion size. Finally, we performed several analyses 
to address a potential incremental value of log-miR-150-5p 
beyond established demographic and vascular risk factors, 
which all pointed in the same direction, i.e., a gain of predic-
tion accuracy by log-miR-150-5p. 
Our findings could have potential clinical implications. Log-
miR-150-5p might help in early decision making concerning 
intensive care monitoring, discharge and rehabilitation plan-
ning. In the setting of trials of new stroke therapies, log-miR-
150-5p could be of value in selecting those, which may benefit 
most of an intervention. For optimal risk stratification, it is 
crucial that prognostic information is available within the first 
hours from symptom onset and that it adds prognostic infor-
mation beyond known established factors, and log-miR-150-
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5p meets this demand. However, before considering the use of 
log-miR-150-5p in clinical practice, the prognostic value of 
log-miR-150-5p needs to be validated in prospective, indepen-
dent, large, multicenter studies according to the recommenda-
tions of the American Heart Association for studies evaluating 
biomarkers in cardiovascular research.30
Conclusions
In conclusion, our results suggest that log-miR-150-5p is a 
novel prognostic biomarker, improving the risk classification for 
mortality in patients with acute ischemic stroke independently 
from traditional demographic, vascular and imaging risk fac-
tors. Further studies are required to validate this finding.
Supplementary Materials
Supplementary materials related to this article can be found 
online at https://doi.org/10.5853/jos.2017.00423.
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Supplementary Figure 1. These figures show the scatter and box plot of the log-miR150 and the risk factors, which were statistically significant in the uni-
variate analyses for mortality. CRP, C-reactive protein; NIHSS, National Institute of Health Stroke Scale; TACS, total anterior circulation syndrome; AF, atrial 
fibrillation.
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